Hereditary Angioedema (HAE)

Takeda touts positive pediatric data in competitive HAE space

Clinical Trials, Hereditary Angioedema (HAE), Pediatric, Pediatric Diseases, Pediatric Rare Diseases, R&D, Takeda, Therapeutics

Takeda Pharmaceutical announced positive results from the Phase III SHP643-301 trial of Takhzyro (lanadelumab) in kids ages 2 to <12 years with hereditary angioedema (HAE). The drug is already approved for HAE in people 12 years and older.

April 12, 2022/by BioSpace

FDA approves Shire drug for rare swelling disorder

FDA, FDA/Regulatory, First-of-its kind, Hereditary Angioedema (HAE), Hereditary Angioedema (HAE), Hereditary Diseases, New Drug Approvals, Potential Blockbusters, Proteins, Rare Diseases

The U.S. FDA approved a first-of-its-kind drug from Shire Plc to treat patients aged 12 and older suffering from a rare hereditary disease that causes swelling.

August 23, 2018/by Reuters Health